RoHS CS19-1 CS19-2 CS19-3 CS19-4 CS19-5 CS19-6 CS19-7 Silicon Diode with Glass Passivation in a Epoxy Encapsulated Ceramic Package Product Environmental Data Sheet
Note: Actual part maydiffer in shape and sizefrom depicted image. (For visual purpose only)
CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Semiconductor Silicon Chip – Glass Passivated
Lead Glass – Acceptable per RoHS Annex 7c-1 (Lead in Glass)
CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Lid - Epoxy CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Package - Ceramic
Document No. DS 15184 Rev.B, ECN 13019 Revision Date: 7/9/2013
RoHS CS19-1 CS19-2 CS19-3 CS19-4 CS19-5 CS19-6 CS19-7 CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Gold Wire CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Die Attach Preform CS19-1 / CS19-2 / CS19-3 / CS19-4 / CS19-5 / CS19-6 / CS19-7 Component Marking Ink
Cyclohexane – 1, 2 – dicarboxylic anhydride
If the total % is less than 100% , the balance is not considered hazardous per OSHA Hazard CommunicationStandard ( 29 CFR 1910.1200)
TOTAL (CS19-1) TOTAL (CS19-2) TOTAL (CS19-3) TOTAL (CS19-4) TOTAL (CS19-5) TOTAL (CS19-6) TOTAL (CS19-7)
603-641-3800 • 888-641-SEMI (7364) • [email protected] • www.aeroflex.com/metelics
RoHS CS19-1 CS19-2 CS19-3 CS19-4 CS19-5 CS19-6 CS19-7 These parts are RoHS Compliant
The products designed by Aeroflex / Metelics as Lead (Pb) – free conform to the requirements for all substancesidentified in the Europeans Unions’ Restrictions on use of Hazardous Substances in Electrical and ElectronicEquipment (RoHS) Directive 2002/95/EC including Lead. Maximum limit does not apply to applicationscovered by the RoHS exemption. Note: Per European Directive RoHS 202/95/EC Annex 7c-1 the use of lead inglass or ceramic other than dielectric ceramic in capacitors (piezoelectronic devices) or in a glass or ceramicmatrix compound are exempt. All values can vary by +/- 20%. The information presented in this document isbelieved to be accurate, reliable and is a result of review of numerous sources including vendor submitteddatasheets. Data is the most current available to Metelics at the time of preparation and is issued as a matterof reference only. No warranty as to accuracy or completeness is expressed or implied. The information onthis document is subject to change without notice. All percentages are calculated from mass data declared. When CAS is unavailable, vendor supplied comments such as “’Proprietary” or “Trade Secret” will bedocumented. ISO 9001:2008 certified companies
54 Grenier Field Road, Londonderry, NH 03053Tel: (603) 641-3800Sales: (888) 641-SEMI (7364)Fax: (603)-641-3500
975 Stewart Drive, Sunnyvale, CA 94085Tel: (408) 737-8181Fax: (408) 733-7645
Aeroflex / Metelics, Inc. reserves the right to make changes to any products andservices herein at any time without notice. Consult Aeroflex or an authorized salesrepresentative to verify that the information in this data sheet is current beforeusing this product. Aeroflex does not assume any responsibility or liability arisingout of the application or use of any product or service described herein, exceptas expressly agreed to in writing by Aeroflex; nor does the purchase, lease, or useof a product or service from Aeroflex convey a license under any patent rights,
Our passion for performance is defined by three
copyrights, trademark rights, or any other of the intellectual rights of Aeroflex or
attributes represented by these three icons:
solution-minded, performance-driven and customer-focused.
Copyright 2012 Aeroflex / Metelics. All rights reserved.
Fall 2011 HEALTHWISE When you pick up your next prescription, you expenses by controlling the market for that may be told a generic equivalent was substituted specifi c drug over a set amount of time. Once for the brand name drug. You may ask yourself, the patent of the brand name drug has expired, “What exactly is a generic?” and “Is this just as other manufacturers
Life | The Abortion Pill (Also Known as RU-486 or Mifeprex) Overview In September 2000, the FDA approved the abortion pill RU-486, now known as mifepristone (brand name: Mifeprex), for use as an abortifacient (abortion-inducing drug). RU-486 is approved for use through the first seven weeks of pregnancy.1 RU-486 is different from the “morning-after pill,” also known as “emergen